Sanofi SA

SNW

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    82,878

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,369.304.70-0.06%
CAC 407,684.1043.83-0.57%
DAX 4023,074.40270.14-1.16%
Dow JONES (US)41,218.8398.60-0.24%
FTSE 1008,595.850.50-0.01%
HKSE22,662.71158.030.70%
NASDAQ17,844.24133.49-0.74%
Nikkei 22536,830.69378.391.04%
NZX 50 Index12,421.090.16-0.00%
S&P 5005,650.3836.29-0.64%
S&P/ASX 2008,151.406.40-0.08%
SSE Composite Index3,316.1137.081.13%

Market Movers